News Jun 02, 2023 Sandoz decides on Basel for headquarters Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected to take place in th...
News May 26, 2023 Researchers at Kantonsspital St.Gallen find new approach for brain tumors St.Gallen - An international team of scientists led by Kantonsspital St.Gallen have developed new research approaches to combat malignant brain t...
News May 26, 2023 UCB: "It's difficult to beat Swiss quality - even the Chinese admit as much." UCB UCB is a global biopharmaceutical company based in Belgium. Since 1996, it has invested more than 600 million Swiss francs in a state-of-the-art ...
Success stories May 25, 2023 Merck : “Switzerland offers attractive and stable conditions for international companies.“ Merck Science and technology leader Merck has been in Switzerland for almost a century. Today it has eight sites, including five manufacturing faciliti...
Success stories May 25, 2023 CSL Behring: “The deciding factors were time to market and the proven track record of the Bern site.” CSL Behring For over a century, CSL Behring (CSLB) has kept its founding promise to help patients suffering from rare and serious diseases. It specializes in...
News May 24, 2023 Latest research shows 20% of European biotechs now headquartered in Switzerland Press release New research conducted by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20% of European biotech companies are now head...
News May 08, 2023 RetinAI partners with Boehringer Ingelheim to improve retinal disease treatment Bern-based RetinAI Medical, a pioneer in clinical and imaging data management software and advanced analytics using AI for ophthalmology, has joi...
News May 05, 2023 Alentis raises 105 million US dollars Alentis Therapeutics has received 105 million US dollars in a series C funding round. It will invest the funds in the phase I and II programs for...
News May 05, 2023 Roche to found Institute for Human Biology Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will be tasked with promoting the b...
News Apr 26, 2023 Western Switzerland’s biotech sector flourishes amidst global challenges Western Switzerland's biotech industry continues to thrive, displaying resilience amidst global challenges. The region's unique ecosystem fosters...
News Mar 29, 2023 Western Switzerland’s sustainability innovators making global impact Western Switzerland is home to a range of sustainability start-ups that are making waves on the international stage.
News Mar 29, 2023 Alithea Genomics secures CHF 500,000 to boost RNA sequencing technology Alithea Genomics has secured a CHF 500,000 Tech Growth loan from the FIT to launch two new products and expand its RNA sequencing technology port...
News Mar 17, 2023 Swiss Biotech Center: innovative solutions for biopharmaceutical development Located at the BioArk in Monthey, Swiss Biotech Center is a leading research and development center in the field of biotechnology.
News Mar 08, 2023 Bachem receives order totaling more than 500 million Swiss francs Bachem has signed a long-term cooperation agreement for the development and production of peptides. It includes a binding order volume of more th...
News Feb 20, 2023 Limula and CSEM collaborate to make cellular therapies more accessible To improve the accessibility of cellular therapies using automation, Limula has received support from the CSEM from the prototyping phase to the ...
News Feb 01, 2023 SSE Group and Hypex Bio join forces for an environmentally friendly explosive solution The Société Suisse des Explosifs (SSE) has entered into a partnership with Swedish company Hypex Bio Explosives Technology to market its new envi...
News Jan 18, 2023 Calciscon enters Eurostars project to improve patient care worldwide Calciscon, together with Amsterdam University Medical Centers and ADMESY, have signed a collaborative agreement for the development of a laborato...
News Jan 16, 2023 Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis STALICLA has acquired global rights for Novartis' drug candidate mavoglurant, a treatment for substance-use disorders and neurodevelopmental diso...